Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

Mariangela Librizzi, James E. Bradner, Robin S. B. Williams, Peter Coxhead, Minghua Wang, Ronald M. Paranal, Mariangela Librizzi, Alexandra Zuckermann, John Spencer, Hiren Patel, Irina Chuckowree, Matthew Guille

Risultato della ricerca: Article

17 Citazioni (Scopus)

Abstract

Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl) methylene)-2-oxoindolin-5-yl)N8- hydroxyoctanediamide 6
Lingua originaleEnglish
pagine (da-a)1829-1833
Numero di pagine5
RivistaMedChemComm
Volume5
Stato di pubblicazionePublished - 2014

Fingerprint

Enzyme inhibition
Vascular Endothelial Growth Factor Receptor-2
Histone Deacetylase Inhibitors
Xenopus
Antineoplastic Agents
Phosphotransferases
Molecular Weight
Molecular weight
Cells
Cell Line
Molecules
Enzymes
Neoplasms
Lead
vorinostat
Semaxinib
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Cita questo

Librizzi, M., Bradner, J. E., Williams, R. S. B., Coxhead, P., Wang, M., Paranal, R. M., ... Guille, M. (2014). Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors. MedChemComm, 5, 1829-1833.

Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors. / Librizzi, Mariangela; Bradner, James E.; Williams, Robin S. B.; Coxhead, Peter; Wang, Minghua; Paranal, Ronald M.; Librizzi, Mariangela; Zuckermann, Alexandra; Spencer, John; Patel, Hiren; Chuckowree, Irina; Guille, Matthew.

In: MedChemComm, Vol. 5, 2014, pag. 1829-1833.

Risultato della ricerca: Article

Librizzi, M, Bradner, JE, Williams, RSB, Coxhead, P, Wang, M, Paranal, RM, Librizzi, M, Zuckermann, A, Spencer, J, Patel, H, Chuckowree, I & Guille, M 2014, 'Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors', MedChemComm, vol. 5, pagg. 1829-1833.
Librizzi M, Bradner JE, Williams RSB, Coxhead P, Wang M, Paranal RM e altri. Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors. MedChemComm. 2014;5:1829-1833.
Librizzi, Mariangela ; Bradner, James E. ; Williams, Robin S. B. ; Coxhead, Peter ; Wang, Minghua ; Paranal, Ronald M. ; Librizzi, Mariangela ; Zuckermann, Alexandra ; Spencer, John ; Patel, Hiren ; Chuckowree, Irina ; Guille, Matthew. / Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors. In: MedChemComm. 2014 ; Vol. 5. pagg. 1829-1833.
@article{66d9fd693ad64301a567a612d8c4da4e,
title = "Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors",
abstract = "Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl) methylene)-2-oxoindolin-5-yl)N8- hydroxyoctanediamide 6",
author = "Mariangela Librizzi and Bradner, {James E.} and Williams, {Robin S. B.} and Peter Coxhead and Minghua Wang and Paranal, {Ronald M.} and Mariangela Librizzi and Alexandra Zuckermann and John Spencer and Hiren Patel and Irina Chuckowree and Matthew Guille",
year = "2014",
language = "English",
volume = "5",
pages = "1829--1833",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",

}

TY - JOUR

T1 - Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

AU - Librizzi, Mariangela

AU - Bradner, James E.

AU - Williams, Robin S. B.

AU - Coxhead, Peter

AU - Wang, Minghua

AU - Paranal, Ronald M.

AU - Librizzi, Mariangela

AU - Zuckermann, Alexandra

AU - Spencer, John

AU - Patel, Hiren

AU - Chuckowree, Irina

AU - Guille, Matthew

PY - 2014

Y1 - 2014

N2 - Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl) methylene)-2-oxoindolin-5-yl)N8- hydroxyoctanediamide 6

AB - Fragments based on the VEGFR2i Semaxanib (SU5416, (vascular endothelial growth factor receptor-2 inhibitor) and the HDACi (histone deacetylase inhibitor) SAHA (suberanilohydroxamic acid) have been merged to form a range of low molecular weight dual action hybrids. Vindication of this approach is provided by SAR, docking studies, in vitro cancer cell line and biochemical enzyme inhibition data as well as in vivo Xenopus data for the lead molecule (Z)-N1-(3-((1H-pyrrol-2-yl) methylene)-2-oxoindolin-5-yl)N8- hydroxyoctanediamide 6

UR - http://hdl.handle.net/10447/101733

M3 - Article

VL - 5

SP - 1829

EP - 1833

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

ER -